Technology | 2008.01.03
Avexa Initiates Phase III ATC Trial
MELBOURNE, Australia--(BUSINESS WIRE)--Biotechnology company Avexa Limited (ASX:AVX) announced today that it has initiated the Phase III program for apricitabine (ATC), its anti-HIV drug.
For more information, please visit
http://home.businesswire.com/portal/site[...]sId=20080103005254&newsLang=en
